1. Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial
- Author
-
Alberto Cecconi, Pablo Martinez-Vives, Alberto Vera, Cristina Lavilla Olleros, Ana Barrios, Eva Fonseca Aizpuru, Pilar Roquero, Susana Hernandez Muñiz, Maria Jose Olivera, Marianela Ciudad, Ruben Pampin Sanchez, Rosa Fernandez-Madera Martínez, Azucena Bautista-Hernández, Elena García Castillo, Gorane Iturricastillo, Elena Ávalos, Diana Prada Cotado, Alvaro Alejandre de Oña, Eduardo Fernandez Carracedo, Ana Marcos-Jimenez, Ancor Sanz-Garcia, Aranzazu Alfranca, Maurizio Cecconi, Hortensia de La Fuente, Maria Angeles Sanz de Benito, Paloma Caballero, Francisco Sanchez-Madrid, Julio Ancochea, Carmen Suarez, Luis Jesus Jimenez-Borreguero, and Fernando Alfonso
- Subjects
Medicine ,Science - Abstract
Abstract Some patients with COVID-19 pneumonia develop an associated cytokine storm syndrome that aggravates the pulmonary disease. These patients may benefit of anti-inflammatory treatment. The role of colchicine in hospitalized patients with COVID-19 pneumonia and established hyperinflammation remains unexplored. In a prospective, randomized controlled, observer-blinded endpoint, investigator-initiated trial, 240 hospitalized patients with COVID-19 pneumonia and established hyperinflammation were randomly allocated to receive oral colchicine or not. The primary efficacy outcome measure was a composite of non-invasive mechanical ventilation (CPAP or BiPAP), admission to the intensive care unit, invasive mechanical ventilation requirement or death. The composite primary outcome occurred in 19.3% of the total study population. The composite primary outcome was similar in the two arms (17% in colchicine group vs. 20.8% in the control group; p = 0.533) and the same applied to each of its individual components. Most patients received steroids (98%) and heparin (99%), with similar doses in both groups. In this trial, including adult patients with COVID-19 pneumonia and associated hyperinflammation, no clinical benefit was observed with short-course colchicine treatment beyond standard care regarding the combined outcome measurement of CPAP/BiPAP use, ICU admission, invasive mechanical ventilation or death (Funded by the Community of Madrid, EudraCT Number: 2020-001841-38; 26/04/2020).
- Published
- 2022
- Full Text
- View/download PDF